Virtual Events Starts: Friday, September 27
City: Kfar Saba
Year Established: 2011
Financing Status: Not currently raising money
Regulatory/Development Status: CE Marked, Pilot clinical trial completed ready to launch FDA pivotal trial
Additional details: Colospan's device is meant to prevent or delay the for need colostomy - the surgical creation of an external bypass for the intestine or colon following the removal of a diseased part. It can be temporary, giving the gut time to heal before the healthy parts of the intestines are reattached, or permanent. Colospan's device creates an internal bypass and can be removed non-surgically after 10 days.
In October 2017, the company announced that it had raised $8M in a funding round, led by healthcare-focused venture capital fund TriVentures and an undisclosed international medical device company. Colospan intends to use the funding for a clinical trial towards approval from the U.S. FDA, and also to market the device in Europe based on its CE Mark approval, received in 2014.
Technology: Colorectal surgery technology aiming to prevent the profound clinical and economic pains associated with colorectal anastomotic leaks and diverting stomas
Investors/Acquirer: Led by healthcare-focused venture capital fund TriVentures and an undisclosed international medical device company.